Know Cancer

forgot password

A Randomized Phase II Study of Androgen Deprivation Versus Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone-Sensitive Metastatic Prostate Cancer

Phase 2
18 Years
Open (Enrolling)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer

Thank you

Trial Information

A Randomized Phase II Study of Androgen Deprivation Versus Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone-Sensitive Metastatic Prostate Cancer


I. To compare the undetectable PSA rate (PSA < 0.2 ng/mL) after seven cycles (28 weeks) of
protocol treatment between those randomized to a LHRH agonist and bicalutamide and those
randomized to a LHRH agonist, bicalutamide and IMC-A12.

Secondary I. To assess the safety and tolerability of the combination of IMC-A12 with a LHRH
agonist and bicalutamide.

II. To compare the proportion of men who do not achieve a PSA of < 4 ng/mL between the two

III. To assess the accuracy of the prognostic model of undetectable PSA that was developed
from SWOG-9346 using current trial data from each arm.

IV. To assess serum samples and peripheral blood mononuclear cells (PBMNC) for
pharmacodynamic activity with potential biomarkers for IMC-A12 (including, but not limited
to: IGF-I, free IGF-I, IGF-II, IGFBP2, IGFBP3, Growth Hormone, insulin and C-peptide)
obtained from optional blood specimens both before initiation of androgen deprivation
therapy and twelve weeks after initiation of combined therapy.

V. To determine baseline pre-treatment circulating tumor cell (CTC) quantities and response
to therapy (for those patients with detectable CTC levels ≥ 1) twelve weeks later.

VI. In the same subset of patients where CTC levels are obtained, determine baseline serum
levels of microRNAs to include but not limited to mi-141 both before initiation of androgen
deprivation therapy and twelve weeks after combined therapy.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive androgen deprivation therapy comprising oral bicalutamide once daily
on days 1-28 and either goserelin subcutaneously or leuprolide acetate intramuscularly every
1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15.
Treatment repeats every 28 days for 7 courses in the absence of disease progression or
unacceptable toxicity.

ARM II: Patients receive androgen deprivation therapy comprising bicalutamide and either
goserelin or leuprolide acetate as in arm I.

After completion of study therapy, patients are followed up every 6 months for 2 years and
then annually for 3 years.

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the prostate

- Metastatic disease as evidenced by soft tissue and/or bony metastases, including
≥ 1 of the following:

- Visceral disease (liver, lung, or other viscera)

- Bone metastases to sites in either the axial (spine, pelvis, ribs, or
skull) and/or the appendicular (clavicle, humerus, or femur) skeleton

- Lymph node disease not considered to be encompassed within a single
radiotherapy port (e.g., above the aortic bifurcation)

- Patients with measurable disease must have radiographic assessment (at least an
abdominal/pelvic CT scan) within the past 28 days

- Patients with non-measurable disease must be assessed (e.g., bone scan) within
the past 42 days

- PSA ≥ 5 ng/mL within 90 days before initiation of androgen-deprivation therapy

- No known brain metastases

- Brain imaging studies not required for patients with no neurologic signs or

- Zubrod performance status (PS) 0-2

- Zubrod PS 3 allowed if due to bone pain

- WBC ≥ 3,000/mm^3

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 9 g/dL

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 3 times ULN (≤ 5 times ULN for liver metastases)

- Creatinine ≤ 2.0 times ULN OR creatinine clearance ≥ 40 mL/min

- INR ≤ 1.5

- PTT ≤ 5 seconds above the ULN

- Hemoglobin A1c (HgA1C) ≤ 7 AND fasting glucose < 160 mg/dL or below ULN

- Patients with diabetes mellitus who meet this criterion are eligible provided
they are on a stable dietary or therapeutic regimen

- Fertile patients must use effective contraception during and for ≥ 3 months after
completion of study therapy

- No known LVEF ≥ 10% below the lower limit of normal

- Patients with suspected LV dysfunction not confirmed by review of medical
history must undergo MUGA or ECHO within 90 days before study entry

- No history of symptomatic congestive heart failure

- No history of allergic reaction attributed to compounds of similar chemical or
biological composition to cixutumumab

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or stage I or II cancer currently in complete remission

- Prior medical castration allowed provided it was initiated within the past 30 days

- Patients on a luteinizing hormone-releasing hormone (LHRH) agonist (e.g.,
leuprolide acetate or goserelin) must be willing to continue the LHRH agonist in
addition to bicalutamide during study treatment

- Patients on a different anti-androgen (e.g., flutamide) must be willing change
to bicalutamide during study treatment

- Prior bilateral orchiectomy allowed provided it was performed within the past 30 days

- At least 28 days since prior non-orchiectomy surgery and recovered

- More than 28 days since prior strontium-89, rhenium-186, rhenium-188, or samarium-153
radionuclide therapy

- At least 28 days since prior radiotherapy or biologic therapy (e.g., vaccines,
immunotherapy, anti-sense agents, small molecules, or monoclonal antibodies) and

- No prior cytotoxic chemotherapy for metastatic prostate cancer

- No prior treatment with agents that directly inhibit IGF or IGFR

- No prior chimerized or murine monoclonal antibody therapy

- No concurrent antiretroviral therapy for HIV-positive patients

- No concurrent treatment with any of the following:

- Chemotherapy

- Hormonal therapy (other than the LHRH agonist and oral anti-androgen)

- Radiotherapy

- Immunotherapy

- Any other anticancer therapy

- 5-alpha reductase inhibitors (e.g., finasteride or dutasteride)

- Ketoconazole

- Diethylstilbestrol/DES

- Other estrogen-based therapy

- Concurrent prophylactic low-dose coumadin or low-molecular weight heparin allowed
provided coagulation criteria are met

- Patients requiring full-dose (therapeutic) anticoagulation are eligible provided
they are on a stable dose of anticoagulation AND the coagulation parameters are
stable within the therapeutic range (e.g., INR 2-3 for patients on therapeutic

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Undetectable PSA rate

Outcome Time Frame:

7 months

Safety Issue:


Principal Investigator

Evan Yu

Investigator Role:

Principal Investigator

Investigator Affiliation:

Southwest Oncology Group


United States: Food and Drug Administration

Study ID:




Start Date:

December 2010

Completion Date:

Related Keywords:

  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer
  • Stage IV Prostate Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Prostatic Neoplasms



H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612
Tripler Army Medical Center Honolulu, Hawaii  96859-5000
Genesys Hurley Cancer Institute Flint, Michigan  48503
Virginia Mason CCOP Seattle, Washington  98101
Evergreen Hospital Medical Center Kirkland, Washington  98033
Spectrum Health Reed City Hospital Reed City, Michigan  49677
Pacific Medical Center-First Hill Seattle, Washington  98104
Fairbanks Memorial Hospital Fairbanks, Alaska  99701